Real-world outcomes of ranibizumab treatment in French patients with visual impairment due to Macular Edema secondary to Retinal Vein Occlusion: 24-month results from the BOREAL-RVO study.

Conclusion Major improvements in BCVA and CRT were observed at Month 3 after the induction phase, and then was sustained up to Month 24, with a slight decrease, probably due to under-treatm ent. This study demonstrated ranibizumab to be a safe and effective treatment for BRVO and CRVO in the real-world setting, although more regular or pro-active treatment could further improve outcomes.
Source: Ophthalmic Research - Category: Opthalmology Source Type: research